Synthesis and biological evaluation of new non-imidazole H3-receptor antagonists of the 2-aminobenzimidazole series

A novel series of non-imidazole H3-receptor antagonists was developed, by chemical modification of a potent lead H3-antagonist composed by an imidazole ring connected through an alkyl spacer to a 2-aminobenzimidazole moiety (e.g., 2-[[3-[4(5)-imidazolyl]propyl]amino]benzimidazole), previously reported by our research group. We investigated whether the removal of the imidazole ring could allow retaining high affinity for the H3-receptor, thanks to the interactions undertaken by the 2-aminobenzimidazole moiety at the binding site. The imidazole ring of the lead was replaced by a basic piperidine or by a lipophilic p-chlorophenoxy substituent, modulating the spacer length from three to eight methylene groups; moreover, the substituents were moved to the 5(6) position of the benzimidazole nucleus. Within both the 2-alkylaminobenzimidazole series and the 5(6)-alkoxy-2-aminobenzimidazole one, the greatest H3-receptor affinity was obtained for the piperidine-substituted compounds, while the presence of the p-chlorophenoxy group resulted in a drop in affinity. The optimal chain length was different in the two series. Even if the new compounds did not reach the high receptor affinity shown by the imidazole-containing lead compound, it was possible to get good H3-antagonist potencies with 2-aminobenzimidazoles having a tertiary amino group at appropriate distance.

The synthesis and biological evaluation of a new class of non-imidazole H3-receptor antagonists, characterized by a 2-aminobenzimidazole fragment connected to a basic or a lipophilic group through an alkyl spacer, are reported. The best affinity values were observed when the 2-aminobenzimidazole was connected to a tertiary amino group at appropriate distance.Figure optionsDownload as PowerPoint slide